How does sibutramine work?

被引：44

作者：

Lean, MEJ ^{[1
]}

机构：

[1] Univ Glasgow, Dept Human Nutr, Royal Infirm, Glasgow G31 2ER, Lanark, Scotland

来源：

INTERNATIONAL JOURNAL OF OBESITY | 2001年 / 25卷 / Suppl 4期

关键词：

sibutramine; serotonin and noradrenaline reuptake inhibitor (SNRI); energy intake; energy expenditure; weight loss;

D O I：

10.1038/sj.ijo.0801931

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sibutramine offers three types of benefit in weight management: by enhancing weight loss, by improving weight maintenance and by reducing the comorbidities of obesity. The clinical effects of sibutramine are explained through its known mode of action as a serotonin (5-HT) and noradrenaline reuptake inhibitor (SNRI). This dual mechanism of action results in two synergistic physiological effects-a reduction in energy intake and an increase in energy expenditure, which combine to promote and maintain weight loss.

引用

页码：S8 / S11

页数：4

共 16 条

[1] Absence of cardiac valve dysfunction in obese patients treated with sibutramine
Bach, DS
Rissanen, AM
Mendel, CM
Shepherd, G
Weinstein, SP
Kelly, F
Seaton, TB
Patel, B
Pekkarinen, TA
Armstrong, WF
[J]. OBESITY RESEARCH, 1999, 7 (04): : 363 - 369
[2] BUTLER SA, 1997, BR J PHARM S, V120, P350
[3] Modalities of the food intake-reducing effect of sibutramine in humans
Chapelot, D
Marmonier, C
Thomas, F
Hanotin, C
[J]. PHYSIOLOGY & BEHAVIOR, 2000, 68 (03) : 299 - 308
[4] Sibutramine: A new weight loss agent without evidence of the abuse potential associated with amphetamines
Cole, JO
Levin, A
Beake, B
Kaiser, PE
Scheinbaum, ML
[J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 231 - 236
[5] Gundlah C, 1997, J PHARMACOL EXP THER, V283, P581
[6] The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
Hansen, DL
Toubro, S
Stock, MJ
Macdonald, IA
Astrup, A
[J]. INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (10) : 1016 - 1024
[7] Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years
Heitmann, BL
Garby, L
[J]. INTERNATIONAL JOURNAL OF OBESITY, 1999, 23 (10) : 1074 - 1078
[8] Effect of sibutramine on weight maintenance after weight loss:: a randomised trial
James, WPT
Astrup, A
Finer, N
Hilsted, J
Kopelman, P
Rössner, S
Saris, WHM
Van Gaal, LF
[J]. LANCET, 2000, 356 (9248) : 2119 - 2125
[9] A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
Jick, H
Vasilakis, C
Weinrauch, LA
Meier, CR
Jick, SS
Derby, LE
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) : 719 - 724
[10] Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release
Kilpatrick, IC
Traut, M
Heal, DJ
[J]. INTERNATIONAL JOURNAL OF OBESITY, 2001, 25 (10) : 1454 - 1458

← 1 2 →